Journal of Thrombosis and Thrombolysis

Papers
(The H4-Index of Journal of Thrombosis and Thrombolysis is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Characteristics and comparisons of acute stroke in “recovered" to “active COVID-19 and “pre-pandemic” in Qatar database54
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection39
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team35
Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia32
Management of bone marrow biopsy related bleeding risks: a retrospective observational study29
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery29
Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians25
Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors25
Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status24
Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate23
Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic21
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry21
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series20
Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy19
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison17
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding17
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes16
0.10621094703674